



(11) **EP 1 982 988 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
04.06.2014 Bulletin 2014/23

(51) Int Cl.:
C07D 493/22 ^(2006.01) **C07D 519/00** ^(2006.01)
C07F 7/18 ^(2006.01) **C07B 61/00** ^(2006.01)

(21) Application number: **07706872.4**

(86) International application number:
PCT/JP2007/050545

(22) Date of filing: **10.01.2007**

(87) International publication number:
WO 2007/083638 (26.07.2007 Gazette 2007/30)

(54) **METHOD OF SYNTHESIS OF CIGUATOXIN CTX1B AND COMPOUNDS USEFUL FOR THE SYNTHESIS OF CIGUATOXIN CTX1B**

VERFAHREN ZUR SYNTHESE VON CIGUATOXIN CTX1B UND VERBINDUNGEN, DIE FÜR DIE SYNTHESE VON CIGUATOXIN CTX1B VON NUTZEN IST

MÉTHODE DE SYNTHÈSE DE CIGUATOXINE CTX1B ET COMPOSÉS UTILE DANS LA SYNTHÈSE DE CIGUATOXINE CTX1B

(84) Designated Contracting States:
ES FR

(30) Priority: **19.01.2006 JP 2006011297**

(43) Date of publication of application:
22.10.2008 Bulletin 2008/43

(73) Proprietor: **Japan Science and Technology Agency**
Kawaguchi-shi,
Saitama 332-0012 (JP)

(72) Inventors:
• **HIRAMA, Masahiro**
Sendai-shi, Miyagi 989-3201 (JP)
• **INOUE, Masayuki**
Bunkyo-ku, Tokyo 113-0033 (JP)

(74) Representative: **Duckworth, Timothy John et al**
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(56) References cited:

- **M. HIRAMA ET AL.: "Total Synthesis of Ciguatoxin CTX3C" SCIENCE, vol. 294, 2001, pages 1904-1907, XP002572475**
- **TATAMI A. ET AL.: 'A concise route to the right wing of ciguatoxin' TETRAHEDRON LETTERS vol. 44, no. 28, 2003, pages 5229 - 5233, XP004430953**
- **KOBAYASHI S. ET AL.: 'Synthesis of the fully functionalized ABCDE ring moiety of ciguatoxin' ORG. LETT. vol. 6, no. 5, 2004, pages 751 - 754, XP003015463**
- **INOUE M. ET AL.: 'First- and second-generation total synthesis of ciguatoxin CTX3C' PROC. NATL. ACAD. SCI. USA vol. 101, no. 33, 2004, pages 12013 - 12018, XP003015464**
- **INOUE M. ET AL.: 'Total synthesis of ciguatoxin and 51-hydroxy CTX3C' J. AM. CHEM. SOC. vol. 128, no. 29, 2006, pages 9352 - 9354, XP003015465**

EP 1 982 988 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

FIELD OF THE INVENTION

5 **[0001]** The present invention relates to the establishment of a method for total synthesis of ciguatoxin CTX1B which is a homolog of ciguatoxin, further, relates to a provision of compounds useful to make possible an effective method for preparation of said total synthesis.

BACKGROUND OF THE INVENTION

10 **[0002]** Food-poisoning, ciguatera caused by poisoning of originally non-toxic fishes, widely occurs in coral reef islands region of subtropical and tropical regions, and more than 50,000 people suffer annually from ciguatera. Although the mortality is not so high, symptoms such as abnormal sensation, diarrhea, lassitude, arthralgia or itching last for several months under some circumstances. Ciguatoxins (CTX), which are isolated and the structure of which is decided as a main originated poison of ciguatera, are macromolecules characterized by fused 13 ether rings and their molecular length is approximately 3 nm, further more than 20 kinds of homolog are existing. Ciguatoxins are produced from dinoflagellate *Gambierdiscus toxicus* and accumulate in fishes by means of food chain. Since approximately 400 kinds of toxic fishes are normal from the view points of appearance, taste and odor, it is not safe to exploit fish sources of southern sea region. Therefore, the development of detective method of ciguatoxins by means of easy and high sensitive immunological measuring method of ciguatoxins is strongly expected.

20 **[0003]** Ciguatoxins bind specifically to voltage-sensitive Na⁺ channels (VSSC) of excitable membranes, activate it and generate toxicity, however, the activation mechanism of ciguatoxins at structural level is not made clear yet. Ciguatoxins exist in nature is very small and cultural production by the dinoflagellate is very slow, detail biological research and the preparation of anti-CTX antibody using natural product is virtually impossible. Under said circumstances, the quantitative supply of natural ciguatoxins by practical chemical synthesis is strongly desired.

25 **[0004]** Inventors of the present invention already proposed a total synthesis of CTX3C, which is one of main homolog of ciguatoxin (non patent document 1, Proc. Natl. Acad. Sci. U.S.A. 101, 12013 12018 (2004)). Further, the inventors developed a Sandwich immunoassay that can detect CTX3C easily (non patent document 2, J. Am. Chem. Soc. 125, 7608-7612 (2003)) and are now investigating to apply it to identification of a ciguatera fish. However, since CTX3C is mainly contained in a herbivorous fish, preparation of an antibody originated to other homolog is necessary for detection of ciguatoxin from a carnivorous fish.

30 **[0005]** Science 2001 vol294 pages 1904-1907 discloses a total synthesis of ciguatoxin CTX3C

35 **[0006]** CTX1B is the most typical ciguatoxin contained mainly in a carnivorous fish and has more complicated structure than CTX3C, and is known as the most historically important ciguatoxin whose structure is firstly decided in 1989. At the decision of structure, 0.3 mg of CTX3B isolated from 4000 kg of poisonous moray is used. However, since it was actually impossible to obtain practical amount of sample from nature, development of total synthesis of CTX1B is awaited for the actual use of CTX1B as a standard sample.

40 **[0007]** Generally, in total synthesis, if partial structure is different, development of a new synthesis route becomes necessary. However, for the purpose to synthesis many ciguatoxin homologs existing in nature in a unified fashion, the inventors have developed convergent total synthesis, which is characterized to be remarkably simple and more reliable compared with competitive methods. By said method, supply of over than several mg of CTX3C became possible up to this time. According to said concept, since there is possibility that carnivorous fishes accumulate ciguatoxin by higher concentration than herbivorous fishes because carnivorous fishes are locating at upper position of food chain than herbivorous fishes and is more dangerous as a ciguatera poisoned fish, the inventors of the present invention considered

45 **[0008]** At the development of a new effective total synthesis, the inventors of the present invention considered to utilize the reaction sequence which were already developed for synthesis of CTX3C. Namely, the inventors considered to apply the coupling of ABCDE ring segments with HIJKLM ring segments and subsequent construction of FG ring to CTX1B. However, since 7-members ring E-structure, and a side chain existing in A ring segments of CTX1B are structurally different from CTX3C, direct application of methodology used in CTX3C was impossible. Therefore, the inventors planned to develop a higher yielding process from a view point of effective preparation of the aimed compound.

55 (1) At the formation of 7-members ring of compound D at radical ring forming reaction, preparation process of CTX3C can not be used. Therefore, the inventors designed compound 5 that has pentafluoroacrylate instead of conventionally used methylacrylate and yield of ring forming reaction is remarkably improved.

(2) At deprotection of naphthylmethyl (NAP) group, side chain of A ring segment is very unstable to acid and compound E acetal intermediate is formed at conventional acid hydrolysis of acetal. Therefore, various investigations for condition are carried out and it is understood that acetal can be removed by condition of 1N hydrochloric ac-



id/methanol, and the total synthesis of CTX1B can be carried out for the first time. Further, at above mentioned development, the inventors considered to utilize HIJKLM ring segments compound A, which was already reported in a paper (non-patent document 3, J. Org. Chem. 69, 2797-2804 (2004)), and compound C (non-patent document 4, J. Org. Lett., 6, 751-754 (2004)) as one of intermediates, according to the thinking that O,S-acetal compound 3, which is the most important intermediate, can be synthesized by coupling reaction developed by the inventors that permits neutral condition.

SUBJECT OF THE INVENTION


[0009] The subject of the present invention is to provide an effective method for total synthesis of CTX1B by high yield. Aiming to accomplish said subject, the inventors of the present invention considered that the designing of an intermediate that can apply an established reaction to be considered rational in synthesis of ciguatoxin analogous compound is important. That is, the subject of this invention is to provide an useful compound that can be used for an effective method for total synthesis of CTX1B, further to link to an improvement of synthesis of ciguatoxin analogous compound. From said points of view, the inventors of the present invention continued investigation and adopted O,S-acetal forming reaction that synthesizes compound 3. and 9-rings forming reaction from compound 6 to 8, further, developed a radical ring-forming reaction to obtain afore mentioned compound D and a deprotection reaction to obtain CTX1B newly, and by synthesizing all new compounds to link the intermediate to aimed compound, and can accomplish afore mentioned subject.

DISCLOSURE OF THE INVENTION


[0010] The first one of the present invention is a method for synthesizing the aimed compound of CTX1B including following 10 processes. First process is comprised of oxidizing double bond in compound A by using osmium tetra oxide to change to a diol derivative of compound A, and after transforming the diol to an aldehyde by oxidation cleavage by using sodium periodate, reducing the aldehyde to alcohol using sodium borohydride to obtain compound 1 (process 1).




Second process is transforming the alcohol of compound 1 to compound 2 using diphenyldisulfide-tributylphosphine (process 2).




15 Third process comprises of transforming the compound 2 to α - chlorosulphide using N-chlorosuccinimide to synthesize the compound B, and synthesizing compound 3 by joining the ABCDE ring segments compound C (Refer to the non-patent document 4, J. Org. Lett., 6, 751-754 (2004)) and the compound B as O,S-acetal using silver triflate (AgOTf) (process 3), under the presence of DTBMP (dimethylsulfoxide).



(process 3).




40 Fourth process is forming the compound 4 by removing TIPS (triisopropylsilyl) group from the compound 3 using TBAF (tetrabutylammonium fluoride) (process 4).



55 Fifth process is forming the compound 5 by joining pentafluorophenylpropiolate and trimethylphosphine to alcohol of above mention compound 4 (process 5).

5

10




compound 5

15

Sixth process comprises of transforming the compound 5 to carboxylic acid compound D by forming G ring part by carrying out radical cyclizing reaction on said compound 5 treating by AIBN (α, α' -azobis(isobutyronitrile)) and tributyltin hydride, and

20

25




compound D

30

transforming to methyl ester by acting trimethylsilyldiazomethane and to form compound 6 (process 6).

35

40




compound 6

45

Seventh process is forming compound 7 by reducing methyl ester of above mentioned compound 6 by using diisobutylaluminum hydrate under lower temperature condition, then transforms to olefin by Wittig reaction (process 7).


50

55




compound 7


Eighth process is forming compound 8 by forming F ring part by carrying out ring closure methathesis reaction acting Grubbs catalyst to above mentioned compound 7 (process 8).



15 Ninth process is synthesizing compound E, 1,2-diol of A ring side chain of which is protected by naphthylacetal, by oxidizing 6 NAP (2-naphthylmethyl) groups using DDQ (2,3-dichloro-5,6-dicyano-1,4 -benzoquinone) and removing 5 NAP groups (process 9).



35 Tenth process is obtaining aimed compound CTX1B by acid treatment of above mentioned compound E (process 10).



45 EFFECT OF THE INVENTION

50 **[0011]** The offering of an effective total synthesis of CTX1B of the present invention is important from the view point that practical amount of said compound to ensure a progress in the research of biological science or a development for detection of Ciguatera poisoned fish can be supplied, and has an effect that can be practically used as a standard specimen of Ciguatera food-poisoning happened in all over the world.


PREFERRED EMBODIMENT OF THE INVENTION

55 **[0012]** The present invention will be illustrated more in detail. A. Since HIJKLM ring segments compound A (J. Org. Chem. 69, 2797-2804 (2004)), which was reported in afore mentioned non-patent document 3, has a structure corresponding to half of CTX1B, said compound A is used as an intermediate for synthesis of CTX1B. By reaction condition mentioned in following reaction formula, double bond of compound A is oxidized by osmium tetra oxide and transformed to diol, then transformed to aldehyde by oxidation cleavage by sodium periodate (at room temperature), after that,

reduced to alcohol using sodium borohydride and obtain compound 1 (yield of these two processes is 91%).


[0013] Alcohol of compound 1 is transformed to compound 2 using diphenyldisulfide-tributylphosphine (at room temperature, yield is 96%).

5




10

15




20




25

30



35




40

45


[0014] Compound 2 is transformed to α -chlorosulphide in 6:1 mixed solvent of carbon tetrachloride and dichloromethane using NCS and compound B is synthesized. Then, ABCDE ring segments compound C, which is already reported in paper (afore mentioned non-patent document 4, J. Org. Lett., 6, 751-754 (2004)), and compound B are joined as O,S-acetal using silver triflate (AgOTf) in 1:5 mixed solvent of carbon tetrachloride and dichloromethane under the presence of DTBMP and compound 3 is obtained (yield to compound C is 63%).

50


55




[0015] TIPS group of compound 3 is removed by TBAF and compound 4 is formed (yield is 92%). Pentafluorophenylpropionate is introduced into alcohol of compound 4 using pentafluorophenylpropionate and trimethylphosphine and compound 5 is formed (yield is 94%).




[0016] Radical cyclizing reaction is carried out on compound 5 by treating with AIBN and tributyltin hydride in toluene at 85°C and G ring part is formed, thus carboxylic acid compound D is obtained. In mixed solvent of benzene and methanol, trimethylsilyldiazomethane is acted to compound D so as to transform to methyl ester, and compound 6 is formed.




[0017] Methyl ester of compound 6 is reduced to aldehyde by diisobutylaluminum hydride under low temperature condition, then transformed to olefin by Wittig reaction and compound 7 is formed. Grubbs catalyst is acted to compound 7 and F ring part is formed by carrying out ring closure metathesis reaction, and compound 8 is obtained.



1) DIBAL, CH₂Cl₂
-100°C to -90°C, 30min
2) Ph₃CHBr, t-BuOK
THF, 0°C, 30min
77% (2 steps)




1st. Grubbs cat. (30mol%)
CH₂Cl₂, 40°C, 1h
78%



[0018] Six NAP groups of compound 8 are oxidized using DDQ and 5 NAP groups is removed, thus compound E characterized that 1,2-diol of A ring side chain is protected by naphthylacetyl is formed. Finally, compound E is treated by 1N hydrochloric acid in methanol solvent and total synthesis of CTX1B, which is aimed compound, is accomplished.


50

55



15


DDQ, CH₂Cl₂ /H₂O = 1, 45 min
 then
 HPLC
 Asahipak ODP 50-6D, CH₃CN/H₂O = 80/20
 flow = 1.0 ml/min, UV 254, 210 nm



30

35

1N HCl, MeOH, rt, 30 min
 then
 HPLC
 Asahipak ODP 50-6D, CH₃CN/H₂O = 60/40
 flow = 1.0 ml/min, UV 215 nm
 42% (2 steps)



50

EXAMPLES


[0019] More concrete synthesis will be shown as Examples, however, these Examples are shown to understand the present invention more easily and not intending the scope of the present invention.

55

Example 1

Synthesis of compound 1

[0020]



[0021] HIJKLM ring segments compound A (151mg, 129 μ mol) is dissolved in mixed solvent (0.1M) of THF (0.86mL) water(0.43mL), then osmium tetra oxide (19mM, t-BuOH solution, 710 μ L, 13.4 μ mol) and NMO (50% aqueous solution, 94 μ L, 402 μ mol) are added and stirred vigorously at room temperature for 2 hours. To this solution, phosphoric acid buffer solution (pH=7.0, 3.0mL, 0.04M) and sodium periodate (120mg, 536 μ mol) are added gradually and stirred at room temperature for 3 hours. Reaction is stopped by adding saturated $\text{Na}_2\text{S}_2\text{O}_3$ aqueous solution to this solution and diluted by ethyl acetate and saturated NaHCO_3 aqueous solution. Water phase is extracted by ethyl acetate for 3 times, and combined organic layer is washed by saturated brine, then is dried by Na_2SO_4 . Solvent is concentrated and crude aldehyde is used to the next reaction without refining.

20 CH_2Cl_2 (5.0mL, 0.25M) solution of aldehyde is cooled to 0°C, and sodium borohydride (25mg, 670 μ mol) is added and stirred for 30 minutes. Reaction is stopped by adding saturated NH_4Cl aqueous solution into this solution and diluted by ethyl acetate. Water phase is extracted by ethyl acetate for 3 times, and combined organic layer is washed by saturated brine, then is dried by Na_2SO_4 . Solvent is concentrated and refined by a flash column, then alcohol of compound 1 (138mg, 1.17 μ L mol) is obtained. Total yield of this 2 processes is 91%. Features of compound 1 are shown in Table 1.


25 (Table 1) $[\alpha]_{\text{D}}^{23}$ -10.3 (c 0.41, CHCl_3); IR (film) ν 2926, 2865, 1723, 1463, 1090 cm^{-1} ^1H NMR (500 MHz, CDCl_3) δ 7.83-7.41 (21H, m, NAPx3), 4.81 (1H, d, J = 12.0 Hz, NAP), 4.79 (1H, d, J = 12.0 Hz, NAP), 4.73 (1H, d, J = 12.0 Hz, NAP), 4.66 (1H, d, J = 12.0 Hz, NAP), 4.61 (1H, d, J = 12.0 Hz, NAP), 4.58 (1H, d, J = 12.0 Hz, NAP), 4.31 (1H, dd, J = 11.5, 5.0 Hz, H34), 4.26 (1H, m, H54), 3.97 (1H, dd, J = 9.5, 1.5 Hz, H55), 3.88- 3.80 (4H, m, H30, H32, H44, H55), 3.64 (1H, m, H30), 3.61 (1H, d, J = 9.5 Hz, H48), 3.43-3.41 (2H, m, H47, H49), 3.39 (1H, ddd, J = 9.5, 3.5, 3.5 Hz, H37), 3.15 (1H, ddd, J = 11.5, 9.5, 5.0 Hz, H36), 3.10 (1H, ddd, J = 11.5, 9.5, 5.0 Hz, H42), 2.98 (1H, ddd, J = 9.5, 2.5, 2.5 Hz, H41), 2.84 (1H, dd, J = 9.0, 4.0 Hz, H45), 2.25-2.14 (6H, m, H31, H35, H43, H46, H53, H53), 1.95 (1H, m, H31), 1.89-1.77 (3H, m, H38, H39, H40), 1.73 (1H, ddd, J = 11.5, 11.5, 11.5 Hz, H35), 1.67-1.53 (4H, m, H38, H40, H50, H51), 1.39 (1H, ddd, J = 11.5, 11.5, 11.5 Hz, H43), 1.18 (3H, s, Me56), 1.09 (3H, d, J = 7.5 Hz, Me58), 1.07-1.02 (30H, m, TIPS, Me57, Me59, Me60)

35 ^{13}C NMR (125 MHz, CDCl_3) δ 136.7, 136.3, 135.6, 133.26, 133.24, 133.1, 132.9, 132.8, 128.1, 127.9, 127.86, 127.83, 127.74, 127.72, 127.69, 127.65, 126.2, 126.14, 126.12, 126.0, 125.9, 125.8, 125.68, 125.65, 108.9, 86.7, 84.6, 82.9, 80.8, 80.0, 79.6, 78.5, 77.8, 74.1, 73.7, 72.1, 71.9, 71.8, 71.4, 71.1, 68.0, 58.7, 42.5, 41.6, 40.4, 40.0, 38.4, 38.2, 31.5, 29.9, 27.5, 22.6, 19.9, 18.4, 18.3, 18.19, 18.14, 15.9, 14.1, 14.0, 13.5, 13.4, 18.0, 12.9

MALDI-TOF MS, calcd. for $\text{C}_{74}\text{H}_{96}\text{NaO}_{10}\text{Si}$ 1199.6620 (M+Na⁺), found for 1199.6620

40 Synthesis of compound 2

[0022]



55 [0023] Into pyridine (1.2mL, 0.1M) solution of compound 1 (138mg, 117 μ mol), PhSSP (153mg, 702 μ mol) and n- PBu_3 (175 μ L, 702 μ mol) are added and stirred at room temperature for 6 hours. Reaction is stopped by adding saturated NH_4Cl aqueous solution into this solution and diluted by ethyl acetate. Water phase is extracted by ethyl acetate for 3

times, and combined organic layer is washed by saturated brine, then is dried by Na_2SO_4 . Solvent is concentrated and refined by a flash column, then thiophenylether of compound 2 (143 mg, 113 μmol , 96%) is obtained. Features of compound 2 are shown in Table 2.

5 (Table 2)

[0024] $[\alpha]_{\text{D}}^{25}$ -3.3 (c 0.47, CHCl_3); IR (film) ν 2927, 2858, 1708, 1464, 1093, 1030 cm^{-1}

^1H NMR (500 MHz, CDCl_3) δ 7.83-7.11 (26H, m, NAPx3, PhS), 4.81 (1H, d, J = 12.0 Hz, NAP), 4.81 (1H, d, J = 12.5 Hz, NAP), 4.76 (1H, d, J = 12.5 Hz, NAP), 4.75 (1H, d, J = 12.0 Hz, NAP), 4.62 (1H, d, J = 12.0 Hz, NAP), 4.59 (1H, d, J = 12.0 Hz, NAP), 4.27 (1H, m, H54), 4.21 (1H, dd, J = 12.0, 5.0 Hz, H34), 3.98 (1H, d, J = 9.5 Hz, H55), 3.86 (1H, ddd, J = 12.0, 9.0, 5.0 Hz, H44), 3.83 (1H, dd, J = 9.5, 5.5 Hz, H55), 3.77 (1H, dd, J = 7.5, 3.5 Hz, H32), 3.62 (1H, d, J = 9.5 Hz, H48), 3.64 (1H, m, H30), 3.44 (1H, d, J = 3.5 Hz, H47), 3.43 (1H, dd, J = 9.5, 9.5 Hz, H49), 3.30 (1H, ddd, J = 10.0, 10.0, 3.0 Hz, H37), 3.17 (1H, ddd, J = 13.5, 9.0, 4.5 Hz, H30), 3.11 (1H, ddd, J = 12.0, 10.0, 5.0 Hz, H42), 3.09 (1H, ddd, J = 12.0, 10.0, 5.0 Hz, H36), 3.00 (1H, ddd, J = 10.0, 10.0, 2.5 Hz, H41), 2.93 (1H, ddd, J = 13.5, 8.5, 7.5 Hz, H30), 2.86 (1H, dd, J = 9.0, 4.5 Hz, H45), 2.20 (1H, ddd, J = 12.0, 5.0, 5.0 Hz, H43), 2.18 (1H, m, H46), 2.16 (1H, m, H53), 2.15 (1H, m, H53), 2.13 (1H, ddd, J = 12.0, 5.0, 5.0 Hz, H35), 2.10 (1H, m, H31), 2.00 (1H, m, H31), 1.86 (1H, m, H40), 1.82 (1H, m, H39), 1.79 (1H, m, H36), 1.72 (1H, ddd, J = 12.0, 12.0, 12.0 Hz, H35), 1.61 (1H, m, H50), 1.59 (1H, m, H51), 1.56 (1H, m, H38), 1.54 (1H, m, H40), 1.39 (1H, ddd, J = 12.0, 12.0, 12.0 Hz, H43), 1.12 (3H, s, Me56), 1.09 (3H, d, J = 7.5 Hz, Me58), 1.07 (3H, d, J = 7.0 Hz, Me57), 1.06 (3H, d, J = 7.0 Hz, Me59), 1.04 (21H, m, TIPS), 1.02 (3H, m, Me60)

^{13}C NMR (125 MHz, CDCl_3) δ 136.8, 136.74, 136.17, 135.6, 133.25, 133.23, 133.1, 132.9, 132.8, 132.7, 128.7, 128.6, 128.1, 127.85, 127.83, 127.73, 127.71, 127.68, 127.63, 126.2, 126.1, 126.0, 125.98, 125.92, 125.8, 125.7, 125.68, 125.64, 125.61, 125.5, 108.9, 86.6, 84.5, 82.9, 80.9, 80.8, 80.1, 78.5, 77.8, 74.2, 73.4, 72.1, 71.8, 71.4, 71.1, 68.5, 60.4, 42.4, 41.5, 40.5, 40.0, 38.4, 38.3, 30.3, 29.6, 28.1, 27.5, 21.0, 19.9, 18.46, 18.43, 18.38, 18.34, 18.2, 18.1, 15.9, 14.17, 14.11, 13.8, 13.5, 13.4, 13.0

25 MALDI-TOF MS, calcd. for $\text{C}_{76}\text{H}_{102}\text{NaO}_{10}\text{SSi}$ 1291.6704 ($\text{M}+\text{Na}^+$), found for 1291.6624


Synthesis of compound 3

[0025]

30

35

40



[0026] N-chlorosuccinimide (2.67mg, 20 μmol) is dissolved in CH_2Cl_2 (50 μL) and added into CCl_4 (280 μL , 0.07M) solution of compound 2 (24.6mg, 19.4 μmol) solution, stirred at room temperature for 2 hours and compound B is formed. This solution is dropped slowly into -80°C cooled CH_2Cl_2 (1.5ml) solution of compound C (11.2mg, 12.1mol), silver triflate (7.5mg, 32.3 μmol) DTBMP (13.3mg, 64.5 μmol) and activated MS4A (40mg), stirred for 5 hours and elevated the temperature to -10°C . This reacted solution is filtrated by 0°C cooled open column and concentrated. After that, refined by a flash column and compound 3, O,S-acetal (16.6mg, 7.57 μmol , 63%) is obtained. Features of compound 3 are shown in Table 3.

50

(Table 3)

[0027] $[\alpha]_{\text{D}}^{23}$ 4.5 (c 1.00, $-\text{CH}_2\text{Cl}_2$); IR (film) ν 2927, 2865, 1775, 1716, 1459, 1344, 1291, 1090, 816 cm^{-1} ;

^1H NMR (500 MHz, C_6D_6) δ 8.02-6.92 (47H, m, NAPx6, PhS), 6.11 (1H, ddd, J = 13.0, 2.5, 2.5 Hz, H22), 5.98 (1H, dd, J = 15.0, 2.5 Hz, H4), 5.93 (1H, dd, J = 15.0, 2.5 Hz, H3), 5.84 (1H, dddd, J = 17.0, 10.0, 5.5, 5.5 Hz, H26), 5.79 (1H, d, J = 11.5 Hz, H17), 5.78 (1H, d, J = 11.5 Hz, H18), 5.70 (1H, add, J = 11.5, 3.0, 3.0 Hz, H6), 5.61 (1H, ddd, J = 13.0, 2.5, 2.5 Hz, H21), 5.53 (1H, m, H7), 5.33 (1H, dd, J = 10.0, 3.0, 3.0 Hz, H30), 5.24 (2H, s, NAP), 5.21 (1H, d, J = 12.5 Hz, NAP), 5.14 (1H, d, J = 12.5 Hz, NAP), 5.06 (1H, dd, J = 17.0, 2.0 Hz, H26'), 4.98 (1H, dd, J = 10.0, 2.0 Hz, H26'), 4.86

55


(1H, d, $J = 12.5$ Hz, NAP), 4.82 (1H, d, $J = 12.5$ Hz, NAP), 4.81 (1H, d, $J = 12.0$ Hz, NAP), 4.62 (1H, d, $J = 12.0$ Hz, NAP), 4.54 (1H, m, H5), 4.51 (2H, s, NAP), 4.47 (1H, dd, $J = 12.0, 5.0$ Hz, H34), 4.38 (1H, dd, $J = 10.0, 3.0$ Hz, H32), 4.32 (2H, s, NAP), 4.23 (1H, m, H23), 4.20 (1H, m, H2), 4.18 (1H, m, H19), 4.15 (1H, m, H44), 4.08 (1H, m, H54), 4.04 (1H, d, $J = 10.0$ Hz, H55), 3.96 (1H, d, $J = 9.5$ Hz, H48), 3.91 (1H, m, H20), 3.78 (1H, dd, $J = 10.0, 5.0$ Hz, H55), 3.75 (1H, dd, $J = 10.0, 2.0$ Hz, H1), 3.73 (1H, dd, $J = 9.5, 9.5$ Hz, H49), 3.71 (1H, d, $J = 8.0$ Hz, H16), 3.67 (1H, dd, $J = 9.0, 9.0$ Hz, H11), 3.65 (1H, m, H24), 3.62 (1H, d, $J = 3.0$ Hz, H47), 3.56 (1H, dd, $J = 9.0, 9.0$ Hz, H10), 3.52 (1H, dd, $J = 10.0, 4.5$ Hz, H1), 3.32 (1H, m, H37), 3.30 (1H, ddd, $J = 9.0, 9.0, 5.5$ Hz, H9), 3.19 (1H, dd, $J = 9.0, 9.0$ Hz, H12), 3.11 (1H, m, H15), 3.10 (1H, m, H41), 3.03 (1H, dd, $J = 9.5, 5.0$ Hz, H45), 3.02 (1H, m, H36), 2.99 (1H, m, H42), 2.93 (1H, ddd, $J = 11.5, 9.0, 4.5$ Hz, H13), 2.85 (1H, m, H31), 2.59 (1H, ddd, $J = 16.0, 9.0, 4.5$ Hz, H8), 2.53 (1H, m, H25), 2.51 (1H, m, H31), 2.49 (1H, m, H46), 2.47 (1H, m, H43), 2.33 (1H, m, H8), 2.31 (1H, m, H35), 2.29 (1H, m, H14), 2.23 (1H, m, H53), 2.21 (1H, m, H53), 2.20 (1H, m, H25), 2.03 (1H, m, H40), 1.97 (1H, m, H50), 1.95 (1H, m, H35), 1.92 (1H, m, H38), 1.83 (1H, m, H39), 1.77 (1H, ddd, $J = 12.0, 12.0, 12.0$ Hz, H43), 1.67 (1H, ddd, $J = 1.5, 11.5, 11.5$ Hz, H14), 1.63 (1H, m, H40), 1.59 (1H, m, H38), 1.54 (1H, m, H51), 1.13 (3H, m, Me58), 1.13 (21H, m, TIPS), 1.12 (3H, m, Me56), 1.11 (3H, d, $J = 6.5$ Hz, Me59), 1.08 (3H, d, $J = 7.0$ Hz, Me60), 0.98 (3H, d, $J = 7.0$ Hz, Me57);

^{13}C NMR (125 MHz, C_6D_6) δ 176.5, 137.6, 137.5, 137.3, 136.9, 136.7, 136.43, 136.41, 135.1, 134.4, 134.2, 134.05, 133.99, 133.97, 133.95, 133.92, 133.57, 133.54, 133.52, 133.4, 133.3, 133.3, 131.4, 131.1, 129.2, 129.1, 128.48, 128.45, 128.41, 128.35, 128.16, 128.13, 128.12, 128.0, 127.7, 126.9, 126.67, 126.65, 126.57, 126.55, 126.46, 126.44, 126.34, 126.29, 126.23, 126.20, 126.15, 126.12, 126.05, 126.02, 126.00, 125.98, 125.92, 125.86, 125.79, 117.4, 109.5, 89.9, 87.3, 85.6, 84.6, 83.5, 83.1, 82.2, 81.8, 81.5, 80.8, 80.5, 79.9, 79.3, 79.2, 79.1, 78.6, 78.2, 76.8, 75.3, 74.7, 74.3, 73.9, 73.5, 73.1, 72.9, 72.8, 71.7, 71.3, 71.1, 68.9, 68.1, 60.1, 43.2, 42.2, 41.5, 40.9, 39.2, 39.1, 38.2, 37.6, 34.9, 34.7, 31.7, 30.2, 29.2, 28.1, 20.2, 18.73, 18.69, 16.3, 14.4, 13.9, 13.6, 11.2

MALDI-TOF MS, calcd. for $\text{C}_{139}\text{H}_{158}\text{NaO}_{19}\text{SSi}$ 2214.0780 ($\text{M} + \text{Na}^+$), found for 2213.9349

Synthesis of compound 4

[0028]



[0029] TBAF (1.0M THF solution, 23 μL , 23 μmol) is added to THF (300 μL , 0.02M) solution of compound 3 (12.6mg, 5.74 μmol) and stirred at 35°C for 4 hours. After this solution is concentrated, refined using a flush column and alcohol of compound 4 (10.78mg, 5.30 μmol , 92%) is obtained. Features of compound 4 are shown in Table 4.

(Table 4)

[0030] $[\alpha]_D^{23} 10.2$ (c 1.00, CH_2Cl_2); IR (film) ν 3221, 2926, 1775, 1715, 1456, 1347, 1177, 1088, 817 cm^{-1} ;
 ^1H NMR (500 MHz, C_6D_6) δ 7.99-6.98 (47H, m, NAPx6, PhS), 6.14 (1H, ddd, $J = 13.0, 3.0, 3.0$ Hz, H22), 5.99 (1H, dd, $J = 16.0, 1.5$ Hz, H4), 5.96 (1H, dd, $J = 16.0, 1.5$ Hz, H3), 5.86 (1H, d, $J = 12.5$ Hz, H17), 5.84 (1H, d, $J = 12.5$ Hz, H18), 5.78 (1H, dddd, $J = 17.0, 10.5, 6.5, 6.6$ Hz, H26), 5.71 (1H, ddd, $J = 13.0, 3.0, 3.0$ Hz, H21), 5.69 (1H, ddd, $J = 11.5, 3.0, 3.0$ Hz, H6), 5.52 (1H, dddd, $J = 11.5, 7.0, 4.0, 3.5$ Hz, H7), 5.23 (2H, s, NAP), 5.20 (1H, dd, $J = 7.0, 6.5$ Hz, H30), 5.01 (1H, dd, $J = 17.0, 2.5$ Hz, H26'), 4.98 (1H, dd, $J = 10.0, 2.5$ Hz, H26'), 4.88 (1H, d, $J = 12.5$ Hz, NAP), 4.85 (1H, d, $J = 12.5$ Hz, NAP), 4.82 (1H, d, $J = 12.0$ Hz, NAP), 4.70 (1H, d, $J = 12.0$ Hz, NAP), 4.65 (1H, d, $J = 12.0$ Hz, NAP), 4.62 (1H, d, $J = 12.0$ Hz, NAP), 4.53 (1H, m, H5), 4.52 (1H, d, $J = 12.0$ Hz, NAP), 4.49 (1H, d, $J = 12.0$ Hz, NAP), 4.40 (1H, ddd, $J = 8.0, 3.0, 3.0$ Hz, H23), 4.34 (2H, s, NAP), 4.28 (1H, dd, $J = 9.0, 3.0$ Hz, H19), 4.21 (1H, m, H44), -4.19 (1H, m, H2), 4.09 (1H, m, H54), 4.07 (1H, d, $J = 9.5$ Hz, H55), 4.01 (1H, m, H20), 3.96 (1H, d, $J = 8.5$ Hz, H48), 3.96 (1H, m, H32), 3.95 (1H, m, H34), 3.83 (1H, d, $J = 8.0$ Hz, H16), 3.82 (1H, dd, $J = 8.5, 8.5$ Hz, H49), 3.81 (1H, dd, $J = 9.5, 4.5$ Hz, H55), 3.70 (1H, dd, $J = 9.0, 9.0$ Hz, H11), 3.69 (1H, dd, $J = 10.5, 3.0$ Hz, H1), 3.66 (1H, d, $J = 3.0$ Hz, H47), 3.61 (1H, ddd, $J = 8.0, 4.0, 4.0$ Hz, H24), 3.53 (1H, dd, $J = 10.5, 4.5$ Hz, H1), 3.51 (1H, dd, $J = 9.0, 9.0$ Hz, H10), 3.30 (1H, m, H9), 3.28 (1H, m, H37), 3.16 (1H, dd, $J = 9.0, 9.0$ Hz, H12), 3.13 (1H, m, H15), 3.07 (1H, dd, $J = 9.5, 4.5$ Hz, H45), 3.05 (1H, m, H41), 2.92

EP 1 982 988 B1


(1H, ddd, $J = 11.5, 9.0, 4.0$ Hz, H13), 2.88 (1H, m, H42), 2.71 (1H, m, H31), 2.70 (1H, m, H36), 2.59 (1H, ddd, $J = 15.5, 8.0, 4.0$ Hz, H8), 2.56 (1H, m, H46), 2.49 (1H, m, H25), 2.46 (1H, m, H31), 2.41 (1H, ddd, $J = 13.0, 5.0, 5.0$ Hz, H43), 2.32 (1H, ddd, $J = 11.5, 4.0, 4.0$ Hz, H14), 2.29 (1H, m, H8), 2.24 (1H, m, H53), 2.23 (1H, m, H53), 2.20 (1H, m, H25), 2.16 (1H, m, H35), 2.05 (1H, m, H50), 2.02 (1H, m, H40), 1.78 (1H, m, H39), 1.76 (1H, m, H35), 1.72 (1H, ddd, $J = 12.5, 12.5, 12.5$ Hz, H43), 1.70 (1H, ddd, $J = 1.5, 11.5, 11.5$ Hz, H14), 1.60 (1H, m, H38), 1.56 (1H, m, H51), 1.52 (1H, m, H40), 1.32 (3H, s, Me56), 1.27 (3H, d, $J = 6.5$ Hz, Me59), 1.18 (1H, m, H38), 1.17 (3H, d, $J = 7.5$ Hz, Me60), 1.16 (3H, d, $J = 6.5$ Hz, Me58), 0.93 (3H, d, $J = 7.5$ Hz, Me57)

^{13}C NMR (125 MHz, C_6D_6) δ 176.4, 137.6, 137.3, 136.9, 136.7, 136.4, 135.4, 135.0, 134.4, 134.00, 133.99, 133.97, 133.95, 133.94, 133.8, 133.7, 133.58, 133.55, 133.52, 132.8, 132.6, 131.0, 129.3, 129.1, 128.8, 128.47, 128.42, 128.35, 128.2, 128.0, 127.7, 127.5, 126.88, 126.85, 126.67, 126.65, 126.59, 126.56, 126.52, 126.49, 126.47, 126.45, 126.38, 126.33, 126.29, 126.23, 126.14, 126.08, 126.00, 125.93, 125.89, 117.4, 109.6, 89.8, 87.34, 87.27, 85.57, 85.52, 84.4, 83.8, 83.59, 83.54, 83.49, 83.1, 82.2, 81.8, 81.5, 80.9, 80.04, 79.99, 79.2, 78.6, 77.5, 76.8, 75.4, 74.9, 73.9, 73.6, 73.5, 72.9, 71.7, 71.3, 71.1, 67.5, 46.7, 46.2, 43.3, 42.3, 41.3, 40.8, 39.2, 38.5, 37.8, 37.6, 37.3, 34.9, 32.0, 30.2, 28.6, 27.9, 23.0, 20.2, 16.3, 14.4;

MALDI-TOF MS, calcd. for $\text{C}_{130}\text{H}_{138}\text{NaO}_{19}\text{S}$ 2057.9451 ($\text{M}+\text{Na}^+$), found for 2057.5975

Synthesis of Compound 5

[0031]



[0032] Into CH_2Cl_2 (300 μL , 0.01M) solution of compound 4 (6.7mg, 3.29 μmol) and pentaphenylpropiotate (3.1mg, 13.2 μmol), PMe_3 (1.0M THF solution, 6.6 μL , 6.6 μmol) is added and stirred at room temperature for 30 minutes. Further, same process to add same equivalent of pentaphenylpropiotate and PMe_3 and to stir at room temperature for 30 minutes is repeated for 4 times. After this solution is concentrated, refined using a flush column and acrylate of compound 5 (7.0mg, 3.08 μmol , 94%) is obtained. Features of compound 5 are shown in Table 5.

(Table 5)

[0033] $[\alpha]_D^{24}$ -6.7 (c 1.00, CH_2Cl_2); IR (film) ν 3055, 2925, 1750, 1637, 1520, 1457, 1088, 817 cm^{-1} ;
 ^1H NMR (500 MHz, C_6D_6) δ 7.99-7.00 (47H, m, NAPx6, PhS), 7.69 (1H, d, $J = 12.0$ Hz, H29), 6.14 (1H, ddd, $J = 12.5, 2.5, 2.5$ Hz, H22), 5.99 (1H, dd, $J = 16.0, 2.5$ Hz, H4), 5.96 (1H, dd, $J = 16.0, 2.5$ Hz, H3), 5.88 (1H, dddd, $J = 17.0, 10.5, 7.0, 7.0$ Hz, H26), 5.84 (1H, d, $J = 13.0$ Hz, H17), 5.82 (1H, d, $J = 13.0$ Hz, H18), 5.69 (1H, ddd, $J = 12.5, 2.5, 2.5$ Hz, H21), 5.67 (1H, ddd, $J = 13.0, 2.0, 2.0$ Hz, H6), 5.58 (1H, d, $J = 12.0$ Hz, H28), 5.53 (1H, m, H7), 5.26 (1H, dd, $J = 10.0, 4.5$ Hz, H30), 5.24 (2H, s, NAP), 5.10 (1H, dd, $J = 17.0, 2.0$ Hz, H26'), 4.98 (1H, dd, $J = 10.5, 2.0$ Hz, H26'), 5.00 (1H, d, $J = 11.5$ Hz, NAP), 4.92 (1H, d, $J = 11.5$ Hz, NAP), 4.85 (2H, s, NAP), 4.81 (1H, d, $J = 12.0$ Hz, NAP), 4.62 (1H, d, $J = 12.0$ Hz, NAP), 4.53 (1H, m, H5), 4.51 (2H, s, NAP), 4.33 (2H, s, NAP), 4.30 (1H, m, H23), 4.23 (1H, m, H44), 4.21 (1H, m, H2), 4.18 (1H, m, H19), 4.09 (1H, m, H54), 4.06 (1H, m, H34), 3.99 (1H, d, $J = 9.0$ Hz, H48), 3.98 (1H, m, H20), 3.97 (1H, m, H32), 3.96 (1H, m, H55), 3.81 (1H, dd, $J = 9.0, 9.0$ Hz, H49), 3.80 (1H, dd, $J = 9.5, 4.5$ Hz, H55), 3.77 (1H, d, $J = 10.0$ Hz, H16), 3.71 (1H, dd, $J = 9.0, 9.0$ Hz, H11), 3.68 (1H, dd, $J = 10.0, 7.0$ Hz, H1), 3.66 (1H, d, $J = 3.5$ Hz, H47), 3.61 (1H, m, H24), 3.56 (1H, dd, $J = 9.0, 9.0$ Hz, H10), 3.52 (1H, dd, $J = 10.0, 4.0$ Hz, H1), 3.31 (1H, ddd, $J = 9.0, 9.0, 4.5$ Hz, H9), 3.21 (1H, m, H37), 3.20 (1H, dd, $J = 9.0, 9.0$ Hz, H12), 3.12 (1H, ddd, $J = 11.5, 10.0, 5.0$ Hz, H15), 3.06 (1H, dd, $J = 9.5, 5.0$ Hz, H45), 3.03 (1H, m, H41), 2.92 (1H, ddd, $J = 11.5, 9.0, 5.0$ Hz, H13), 2.89 (1H, m, H42), 2.73 (1H, m, H36), 2.62 (1H, m, H8), 2.60 (1H, m, H31), 2.57 (1H, m, H46), 2.54 (1H, m, H25), 2.40 (1H, m, H31), 2.35 (1H, m, H8), 2.32 (1H, m, H43), 2.29 (1H, m, H14), 2.27 (1H, m, H25), 2.23 (1H, m, H53), 2.22 (1H, m, H53), 2.03 (1H, m, H50), 2.00 (1H, m, H40), 1.86 (1H, m, H35), 1.76 (1H, m, H38), 1.72 (1H, m, H39), 1.68 (1H, ddd, $J = 11.5, 11.5, 11.5$ Hz, H43),


1.68 (1H, ddd, $J = 1.5, 11.5, 11.5$ Hz, H14), 1.59 (1H, m, H35), 1.56 (1H, m, H40), 1.54 (1H, m, H51), 1.36 (1H, m, H38), 1.25 (3H, d, $J = 6.0$ Hz, Me59), 1.16 (3H, d, $J = 7.5$ Hz, Me58), 1.14 (3H, d, $J = 7.0$ Hz, Me60), 1.02 (3H, s, Me56), 0.91 (3H, d, $J = 7.5$ Hz, Me57);

^{13}C NMR (125 MHz, C_6D_6) δ 165.21, 163.52, 142.9, 142.8, 141.6, 140.9, 140.4, 139.2, 139.1, 137.9, 137.6, 137.1, 136.9, 136.7, 136.5, 136.4, 135.4, 135.0, 134.4, 134.00, 133.99, 133.97, 133.95, 133.93, 133.91, 133.58, 133.56, 133.52, 133.47, 133.37, 131.6, 130.9, 129.4, 129.3, 129.1, 128.7, 128.6, 128.5, 128.42, 128.38, 128.37, 128.35, 128.14, 128.12, 128.0, 126.9, 126.8, 126.65, 126.64, 126.60, 126.58, 126.55, 126.52, 126.48, 126.46, 126.39, 126.37, 126.29, 126.27, 126.23, 126.22, 126.15, 126.10, 125.99, 125.92, 125.88, 125.75, 125.70, 117.6, 109.5, 95.7, 89.0, 87.4, 87.3, 85.5, 84.6, 83.7, 83.5, 83.4, 82.4, 82.3, 81.8, 81.7, 81.5, 80.8, 79.34, 79.30, 79.2, 79.1, 78.6, 78.0, 76.8, 75.4, 74.8, 74.4, 73.9, 73.8, 73.6, 73.5, 72.9, 72.8, 71.8, 71.3, 71.1, 46.57, 46.0, 43.3, 42.2, 41.2, 40.9, 39.2, 38.2, 37.6, 36.5, 34.9, 34.7, 30.5, 30.2, 28.4, 27.9, 20.2, 16.3, 14.0, 13.7;

MALDI-TOF MS, calcd. for $\text{C}_{139}\text{H}_{139}\text{F}_5\text{NaO}_{21}\text{S}$ 2293.9347 ($\text{M}+\text{Na}^+$), found for 2293.9377

Synthesis of Compound 6

[0034]



[0035] Degassed toluene (4.3mL, 0.001M solution of compound 5 (9.7mg, 4.27 μ mol), AIBN (7.1mg, 43 μ mol) and $n\text{-Bu}_3\text{SnH}$ (58 μ L, 215 μ mol) is heated to 85°C and stirred for 3 hours. After this solution is cooled down, refined directly using a flush column and carboxylic acid of compound D (5.0mg, 2.50 μ mol, 59%) is obtained. Compound D is not refined more and used to the next reaction.

[0036] TMSCHN_2 (2.0M hexane solution, 13 μ L, 25mol) is added into mixed solution (0.01M) of benzene (0.86mL) -methanol (0.43mL) of carboxylic acid (5.0mg, 2.50 μ mol) of compound D and stirred for 30minutes, This solution is diluted by benzene and water, and reaction is stopped by dropping acetic acid. Ethyl acetate and saturated NaHCO_3 aqueous solution, and water phase is extracted by ethyl acetate for 3 times. Organic layer is washed by saturated brine and dried by Na_2SO_4 . Solvent is concentrated, refined by a flush column and methyl ester (4.2mg, 2.09 μ mol, 84%) of compound 6 is obtained. Features of compound 6 are shown in Table 6.

(Table 6)

[0037] $[\alpha]_{\text{D}}^{25}$ 10.6 (c 0.50, CH_2Cl_2 IR (film) ν 2924, 2854, 1738, 1456, 1334, 1270, 1089, 817 cm^{-1} ;


^1H NMR (500 MHz, C_6D_6) δ 7.99-7.01 (42H, m, NAPx6), 6.00 (1H, dd, $J = 16.0, 2.0$ Hz, H4), 5.96 (1H, dd, $J = 16.0, 2.0$ Hz, H3), 5.95 (1H, dddd, $J = 17.0, 10.5, 7.0, 7.0$ Hz, H26), 5.86 (1H, d, $J = 13.0$ Hz, H17), 5.84 (1H, d, $J = 13.0$ Hz, H18), 5.69 (1H, ddd, $J = 11.0, 3.0, 3.0$ Hz, H6), 5.53 (1H, d, $J = 11.0$ Hz, H21), 5.52 (1H, m, H7), 5.51 (1H, d, $J = 11.0$ Hz, H22), 5.23 (2H, s, NAP), 5.23 (1H, d, $J = 12.5$ Hz, NAP), 5.17 (1H, dd, $J = 17.0, 3.0$ Hz, H26'), 5.07 (1H, dd, $J = 10.5, 3.0$ Hz, H26''), 5.01 (1H, d, $J = 12.5$ Hz, NAP), 4.87 (1H, d, $J = 12.5$ Hz, NAP), 4.84 (1H, d, $J = 12.5$ Hz, NAP), 4.81 (1H, d, $J = 12.0$ Hz, NAP), 4.62 (1H, d, $J = 12.0$ Hz, NAP), 4.54 (1H, m, H5), 4.51 (2H, s, NAP), 5.42 (1H, dd, $J = 7.0, 7.0$ Hz, H29), 4.33 (2H, s, NAP), 4.27 (1H, d, $J = 9.0$ Hz, H19), 4.19 (1H, m, H44), 4.17 (1H, m, H2), 4.09 (1H, m, H54), 4.06 (1H, d, $J = 10.5$ Hz, H30), 3.99 (1H, d, $J = 9.5$ Hz, H23), 3.98 (1H, m, H55), 3.96 (1H, d, $J = 9.0$ Hz, H20), 3.83 (1H, d, $J = 10.0$ Hz, H16), 3.81 (1H, m, H55), 3.80 (1H, m, H32), 3.69 (1H, dd, $J = 9.0, 3.5$ Hz, H1), 3.68 (1H, dd, $J = 9.0, 9.0$ Hz, H11), 3.68 (1H, d, $J = 9.0$ Hz, H48), 3.65 (1H, d, $J = 3.0$ Hz, H47), 3.63 (1H, m, H34), 3.60 (1H, m, H24), 3.53 (1H, dd, $J = 9.0, 3.5$ Hz, H1), 3.52 (1H, dd, $J = 9.0, 9.0$ Hz, H49), 3.49 (1H, m, H37), 3.43 (1H, dd, $J = 9.0, 9.0$ Hz, H10), 3.31 (3H, s, MeO), 3.30 (1H, m, H9), 3.15 (1H, ddd, $J = 11.5, 10.0, 4.5$ Hz, H15), 3.10 (1H, m, H41), 3.09 (1H, dd, $J = 9.0, 9.0$ Hz, H12), 3.06 (1H, dd, $J = 9.5, 4.5$ Hz, H45), 2.98 (1H, m, H36), 2.94 (1H, m, H42), 2.92 (1H, m, H13), 2.58 (1H, m, H8), 2.57 (1H, m, H25), 2.55 (1H, m, H46), 2.44 (1H, dd, $J = 11.0, 7.0$ Hz, H28), 2.40 (1H, m, H14), 2.38 (1H, m, H25), 2.36 (1H, m, H43), 2.34 (1H, m, H8), 2.24 (1H, m, H53), 2.23 (1H, m, H53), 2.14 (1H, dd, $J = 11.0, 7.0$ Hz, H28), 2.11 (1H, m, H35), 2.08

(1H, m, H50), 2.07 (1H, m, H31), 2.03 (1H, m, H38), 2.01 (1H, m, H40), 1.89 (1H, m, H31), 1.86 (1H, m, H35), 1.85 (1H, m, H39), 1.72 (1H, ddd, $J = 11.5, 11.5, 11.5$ Hz, H43), 1.70 (1H, ddd, $J = 1.5, 11.5, 11.5$ Hz, H14), 1.65 (1H, m, H40), 1.59 (1H, m, H38), 1.57 (1H, m, H51), 1.29 (3H, s, Me56), 1.26 (3H, d, $J = 6.0$ Hz, Me59), 1.15 (3H, d, $J = 6.5$ Hz, Me58), 1.10 (3H, d, $J = 8.0$ Hz, Me60), 0.96 (3H, d, $J = 7.0$ Hz, Me57);

^{13}C NMR (125 MHz, C_6D_6) δ 170.80, 137.9, 137.7, 137.3, 136.9, 136.7, 136.5, 135.3, 135.2, 134.4, 134.3, 134.2, 134.04, 133.99, 133.96, 133.94, 133.61, 133.59, 133.55, 133.53, 131.4, 130.0, 129.3, 129.2, 128.6, 128.46, 128.42, 128.38, 128.35, 128.30, 128.16, 128.14, 128.0, 126.9, 126.8, 126.66, 126.63, 126.58, 126.55, 126.47, 126.44, 126.35, 126.29, 126.22, 126.13, 126.06, 125.99, 125.94, 125.88, 125.7, 117.4, 109.5, 87.4, 87.1, 85.6, 84.2, 83.8, 83.4, 82.4, 82.2, 81.74, 81.66, 81.2, 80.9, 80.26, 80.22, 80.1, 79.4, 79.22, 79.18, 78.6, 78.5, 76.8, 75.3, 74.9, 74.1, 73.9, 73.6, 73.5, 72.9, 72.8, 71.7, 71.3, 71.1, 47.2, 46.3, 43.3, 42.3, 41.4, 40.7, 39.9, 39.2, 38.5, 37.6, 36.1, 34.9, 32.6, 32.4, 32.0, 28.2, 27.1, 23.1, 20.2, 17.3, 16.4, 14.0, 13.8, 9.7; MALDI-TOF MS, calcd. for $\text{C}_{128}\text{H}_{138}\text{NaO}_{21}$ 2033.9628 (M+Na⁺), found for 2033.9634

Synthesis of compound 7

[0038]



[0039] DIBAL solution (0.9M hexane solution, 17 μL , 15.1 μmol) is dropped slowly to CH_2 (1.5ml, 0.001M) solution of compound 6 (3.2mg, 1.51 μmol), which is cooled down to -100°C , stirred for 30 minutes and elevate the temperature to -90°C . Reaction is stopped by adding Ethyl acetate and saturated NH_4Cl aqueous solution and diluted by ethyl acetate. Water phase is extracted by ethyl acetate for 3 times and combined organic layer is washed by saturated brine and dried by Na_2SO_4 . Solvent is concentrated and crude aldehyde is obtained. This aldehyde is not refined and used in next reaction.

THF (1.0mL, 0.001M) of triphenylphosphonium bromide (54mg, 151 μmol) is treated with *t*-BuOK (8.4mg, 75 μmol) at 0°C , and mixture is stirred at 0°C for 20 minutes. THF solution (0.5mL) of aldehyde is introduced and is stirred at $^\circ\text{C}$ for 30 minutes. Reaction is stopped by adding saturated NH_4Cl aqueous solution and water phase is extracted by ethyl acetate, 3 times. Organic layer is washed with saturated brine, then dried by Na_2SO_4 . Solvent is concentrated and refined by a flush column and hexane (2.3mg, 1.16 μmol , total of two process is 77%) of compound 7 is obtained. Features of compound 7 are shown in Table 7.

(Table 7)

[0040] $[\alpha]_D^{27} 2.2$ (c 0.50, CH_2Cl_2 IR (film) ν 2924, 1727, 1514, 1438, 1262, 1175, 1089, 818 cm^{-1} ;

^1H NMR (500 MHz, C_6D_6) δ 7.99-7.01 (42H, m, NAPx6), 5.99 (1H, m, H4), 5.97 (1H, m, H3), 5.92 (1H, dddd, $J = 17.0, 10.0, 7.0, 7.0$ Hz, H26), 5.88 (1H, dddd, $J = 17.0, 10.5, 7.0, 7.0$ Hz, H27), 5.86 (1H, d, $J = 12.0$ Hz, H17), 5.84 (1H, d, $J = 12.0$ Hz, H18), 5.70 (1H, ddd, $J = 11.5, 3.0, 3.0$ Hz, H6), 5.53 (1H, m, H7), 5.51 (1H, d, $J = 13.0$ Hz, H21), 5.46 (1H, d, $J = 13.0$ Hz, H22), 5.24 (2H, s, NAP), 5.20 (1H, d, $J = 12.0$ Hz, NAP), 5.13 (1H, dd, $J = 17.0, 2.5$ Hz, H26'), 5.06 (1H, dd, $J = 10.0, 2.5$ Hz, H26''), 5.05 (1H, dd, $J = 10.5, 2.0$ Hz, H27'), 5.04 (1H, d, $J = 12.0$ Hz, NAP), 5.01 (1H, dd, $J = 17.0, 2.5$ Hz, H27''), 4.86 (1H, d, $J = 12.5$ Hz, NAP), 4.83 (1H, d, $J = 12.5$ Hz, NAP), 4.81 (1H, d, $J = 12.5$ Hz, NAP), 4.62 (1H, d, $J = 12.5$ Hz, NAP), 4.54 (1H, m, H5), 4.51 (2H, s, NAP), 4.33 (2H, s, NAP), 4.20 (1H, m, H2), 4.18 (1H, d, $J = 9.0$ Hz, H19), 4.17 (1H, m, H44), 4.10 (1H, m, H30), 4.08 (1H, m, H54), 4.06 (1H, m, H55), 3.99 (1H, d, $J = 9.5$ Hz, H48), 3.94 (1H, d, $J = 9.0$ Hz, H20), 3.89 (1H, dd, $J = 7.0, 7.0$ Hz, H29), 3.83 (1H, d, $J = 9.5$ Hz, H16), 3.81 (1H, m, H55), 3.80 (1H, dd, $J = 9.5, 9.5$ Hz, H49), 3.77 (1H, d, $J = 9.0$ Hz, H23), 3.70 (1H, dd, $J = 9.0, 3.5$ Hz, H11), 3.69 (1H, dd, $J = 10.5, 4.0$ Hz, H1), 3.66 (1H, d, $J = 3.5$ Hz, H47), 3.57 (1H, dd, $J = 8.5, 4.5$ Hz, H34), 3.54 (1H, m, H24), 3.52 (1H, dd, $J = 10.5, 4.0$ Hz, H1), 3.52 (1H, m, H32), 3.51 (1H, m, H37), 3.48 (1H, dd, $J = 9.0, 9.0$ Hz, H10), 3.29 (1H, ddd, $J = 9.0, 9.0, 4.0$ Hz, H9), 3.16 (1H, ddd, $J = 11.5, 9.5, 4.5$ Hz, H15), 3.14 (1H, dd, $J = 9.0, 9.0$ Hz, H12), 3.11 (1H, m, H41), 3.06 (1H, dd, $J = 8.5,$


4.5 Hz, H45), 2.98 (1H, m, H36), 2.96 (1H, m, H42), 2.93 (1H, m, H13), 2.58 (1H, ddd, $J = 16.0, 9.0, 4.5$ Hz, H8), 2.55 (1H, m, H46), 2.53 (1H, m, H25), 2.41 (1H, ddd, $J = 11.5, 4.5, 4.5$ Hz, H43), 2.35 (1H, ddd, $J = 11.5, 4.5, 4.5$ Hz, H14), 2.29 (1H, m, H8), 2.27 (1H, m, H25), 2.24 (1H, m, H53), 2.23 (1H, m, H53), 2.22 (1H, m, H28), 2.14 (1H, m, H31), 2.13 (1H, m, H35), 2.07 (1H, m, H38), 2.06 (1H, m, H40), 2.04 (1H, m, H50), 2.02 (1H, m, H28), 1.96 (1H, m, H31), 1.93 (1H, m, H35), 1.90 (1H, m, H39), 1.73 (1H, ddd, $J = 11.5, 11.5, 11.5$ Hz, H43), 1.71 (1H, ddd, $J = 1.5, 11.5, 11.5$ Hz, H14), 1.65 (1H, m, H40), 1.59 (1H, m, H38), 1.56 (1H, m, H51), 1.27 (3H, d, $J = 7.0$ Hz, Me59), 1.25 (3H, s, Me56), 1.23 (3H, d, $J = 7.5$ Hz, Me60), 1.22 (3H, d, $J = 6.5$ Hz, Me58), 0.96 (3H, d, $J = 6.0$ Hz, Me57);

^{13}C NMR (125 MHz, C_6D_6) δ 137.6, 137.3, 136.9, 136.7, 136.5, 135.4, 135.2, 135.0, 134.4, 134.2, 134.1, 134.04, 134.01, 133.99, 133.98, 133.96, 133.95, 133.92, 133.59, 133.55, 133.53, 133.31, 131.5, 131.1, 130.8, 130.4, 129.3, 129.2, 128.47, 128.42, 128.35, 128.2, 126.9, 126.66, 126.65, 126.58, 126.56, 126.54, 126.48, 126.45, 126.34, 126.29, 126.24, 126.23, 126.21, 126.13, 126.07, 126.00, 125.94, 125.88, 125.7, 124.93, 124.88, 117.4, 109.5, 87.4, 87.2, 85.6, 84.5, 83.8, 83.50, 83.46, 82.8, 82.2, 81.8, 81.2, 80.83, 80.77, 80.4, 79.4, 79.22, 79.18, 78.6, 76.8, 75.4, 74.9, 74.0, 73.9, 73.6, 73.51, 73.46, 72.84, 72.81, 72.5, 71.83, 71.75, 71.3, 71.1, 63.3, 62.4, 46.4, 43.3, 42.3, 41.4, 40.7, 40.3, 39.2, 38.5, 37.6, 36.3, 34.9, 34.4, 32.0, 27.7, 27.3, 25.4, 24.2, 22.0, 20.2, 16.4, 14.2, 14.0, 9.8;

MALDI-TOF MS, calcd. for $\text{C}_{128}\text{H}_{138}\text{NaO}_{19}$ 2001.9730 ($\text{M}+\text{Na}^+$), found for 2001.9711

Synthesis of compound 8

[0041]



[0042] $(\text{PCy}_3)_2\text{Cl}_2\text{Ru}=\text{CHPh}$ (Grubbs catalyst, 0.2mg, 0.24 μmol) is added to CH_2Cl_2 (1.0mL, 0.7mM) solution of frozen and de-aired compound 7 (1.3mg, 0.66 μmol) and stirred at 40°C for 4 hours. To this solution, Et_3N (0.1mL) is introduced and reaction is stopped, then concentrated and refined by a flush column, thus pentaene (1.0mg, 0.51 μmol , 78%) of compound 8 is obtained. Features of compound 8 are shown in Table 8.

(Table 8)

[0043] $[\alpha]_D^{25} -6.2$ (c 0.10, CH_2Cl_2); IR (film) ν 2924, 2854, 1736, 1457, 1268, 1092 cm^{-1} ;

^1H NMR (500 MHz, C_6D_6) δ 8.00-7.00 (42H, m, NAPx6), 5.99 (1H, dd, $J = 15.5, 3.5$ Hz, H4), 5.95 (1H, dd, $J = 15.5, 3.5$ Hz, H3), 5.89 (1H, d, $J = 13.0$ Hz, H18), 5.88 (1H, m, H26), 5.88 (1H, m, H27), 5.86 (1H, m, H21), 5.78 (1H, d, $J = 13.0$ Hz, H17), 5.69 (1H, ddd, $J = 11.0, 3.0, 3.0$ Hz, H6), 5.57 (1H, m, H22), 5.53 (1H, m, H7), 5.26 (2H, s, NAP), 4.99 (1H, d, $J = 12.5$ Hz, NAP), 4.88 (1H, d, $J = 12.5$ Hz, NAP), 4.84 (1H, d, $J = 12.5$ Hz, NAP), 4.83 (1H, d, $J = 12.5$ Hz, NAP), 4.81 (1H, d, $J = 12.5$ Hz, NAP), 4.61 (1H, d, $J = 12.5$ Hz, NAP), 4.55 (1H, m, H5), 4.50 (2H, s, NAP), 4.34 (2H, s, NAP), 4.26 (1H, m, H44), 4.19 (1H, m, H2), 4.10 (1H, m, H54), 4.07 (1H, d, $J = 9.5$ Hz, H48), 4.01 (1H, d, $J = 10.0$ Hz, H55), 4.00 (1H, d, $J = 9.0$ Hz, H20), 3.98 (1H, m, H23), 3.92 (1H, m, H19), 3.84 (1H, d, $J = 9.0$ Hz, H16), 3.83 (1H, dd, $J = 9.5, 9.5$ Hz, H49), 3.81 (1H, dd, $J = 10.0, 5.0$ Hz, H55), 3.74 (1H, dd, $J = 9.0, 3.5$ Hz, H11), 3.72 (1H, dd, $J = 6.5, 6.5$ Hz, H30), 3.67 (1H, dd, $J = 10.0, 7.0$ Hz, H1), 3.67 (1H, d, $J = 3.5$ Hz, H47), 3.59 (1H, dd, $J = 9.0, 9.0$ Hz, H10), 3.53 (1H, m, H32), 3.52 (1H, dd, $J = 10.0, 4.0$ Hz, H1), 3.51 (1H, m, H29), 3.49 (1H, m, H24), 3.46 (1H, m, H37), 3.33 (1H, ddd, $J = 9.0, 9.0, 4.0$ Hz, H9), 3.27 (1H, dd, $J = 9.0, 9.0$ Hz, H12), 3.17 (1H, ddd, $J = 11.5, 9.0, 4.0$ Hz, H15), 3.13 (1H, m, H41), 3.10 (1H, dd, $J = 9.0, 4.5$ Hz, H45), 3.05 (1H, m, H42), 3.03 (1H, m, H34), 2.96 (1H, m, H13), 2.94 (1H, m, H36), 2.87 (1H, m, H25), 2.86 (1H, m, H28), 2.61 (1H, ddd, $J = 16.0, 8.0, 4.0$ Hz, H8), 2.58 (1H, m, H25), 2.58 (1H, m, H28), 2.56 (1H, m, H46), 2.48 (1H, ddd, $J = 12.0, 5.0, 5.0$ Hz, H43), 2.39 (1H, m, H31), 2.34 (1H, m, H14), 2.33 (1H, m, H8), 2.24 (1H, m, H53), 2.23 (1H, m, H53), 2.21 (1H, m, H31), 2.14 (1H, m, H50), 2.09 (1H, m, H40), 2.06 (1H, m, H35), 2.02 (1H, m, H38), 1.87 (1H, m, H39), 1.86 (1H, m, H35), 1.79 (1H, ddd, $J = 12.0, 12.0, 12.0$ Hz, H43), 1.72 (1H, ddd, $J = 11.5, 11.5, 11.5$ Hz, H14), 1.66 (1H, m, H40), 1.60 (1H, m, H38), 1.56 (1H, m, H51), 1.36 (3H, s, Me56), 1.29 (3H, d, $J = 6.5$ Hz, Me59), 1.17 (3H, d, $J = 7.5$ Hz, Me58), 1.16 (3H, d, $J = 7.0$ Hz, Me60), 0.98 (3H, d, $J = 7.5$ Hz, Me57); MALDI-TOF MS, calcd. for


EP 1 982 988 B1

C₁₂₆H₁₃₄NaO₁₉ 1973.9421 (M+Na⁺), found for 1973.9417

[0044] Synthesis of aimed compound CTX1B.

5

10



15 [0045] DDQ (1.6mg, 6.9 μmol) is added to CH₂Cl₂ (100 μ L)-water(100 μ L) solution of compound 8 (450 μ g, 0.23 μ mol) and stirred at room temperature for 45 minutes. Na₂S₂O₃ aqueous solution is added and reaction is stopped, and diluted by ethyl acetate and saturated NaHCO₃ aqueous solution. Water phase is extracted by ethyl acetate for 5 times and combined organic layer is washed by saturated brine, then solvent is concentrated. Obtained mixture is refined by HPLC and compound E is obtained. Hydrochloric acid (1N, 50 μ L) is added to methanol (200 μ L) solution of
20 compound E and stirred at room temperature for 30 minutes. Saturated NaHCO₃ aqueous solution is added to this solution and reaction is stopped, then concentrated. This mixture is diluted by water and ethyl acetate for 5 times, and combined organic layer is concentrated. Crude CTX1B is refined by HPLC and CTX1B (108 μ mg, 0.097 μ mol, 42%) is obtained. Features of synthesized CTX1B are shown in Table 9.

25 (Table 9)

[0046] ¹H NMR (500 MHz, C₆D₅N) δ 7.30 (1H, d, *J* = 4.0 Hz, OH11), 6.75 (1H, d, *J* = 3.5 Hz, OH47), 6.63 (1H, d, *J* = 4.0 Hz, OH2), 6.52 (1H, d, *J* = 4.0 Hz, OH54), 6.39 (1H, t, *J* = 5.0 Hz, OH1), 6.38 (1H, dd, *J* = 15.0, 3.0 Hz, H4), 6.35 (1H, dd, *J* = 15.0, 3.0 Hz, H3), 6.03 (1H, d, *J* = 13.0 Hz, H22), 5.97 (1H, m, H26), 5.97 (1H, m, H27), 5.91 (1H, ddd, *J* = 11.5, 3.0, 3.0 Hz, H6), 5.89 (1H, d, *J* = 12.5 Hz, H18), 5.53 (1H, dddd, *J* = 11.5, 8.0, 3.0, 3.0 Hz, H7), 5.74 (1H, d, *J* = 12.5 Hz, H17), 5.67 (1H, m, H21), 5.26 (1H, m, OH54), 4.86 (1H, m, H5), 4.86 (1H, m, H54), 4.69 (1H, m, H2), 4.48 (1H, ddd, *J* = 12.0, 10.0, 5.0 Hz, H44), 4.22 (1H, dd, *J* = 3.5, 3.5 Hz, H47), 4.21 (1H, m, H20), 4.19 (1H, m, H55), 4.17 (1H, m, H55), 4.16 (1H, m, H32), 4.10 (1H, ddd, *J* = 9.0, 9.0, 4.0 Hz, H11), 4.07 (1H, d, *J* = 10.0 Hz, H48), 4.05 (1H, m, H19), 4.03 (1H, m, H23), 4.02 (1H, d, *J* = 10.0 Hz, H16), 4.00 (1H, ddd, *J* = 10.0, 5.0, 5.0 Hz, H1), 3.98 (1H, dd, *J* = 10.0, 5.0, 5.0 Hz, H1), 3.97 (1H, dd, *J* = 10.0, 10.0 Hz, H49), 3.78 (1H, m, H29), 3.76 (1H, dd, *J* = 9.0, 9.0 Hz, H10), 3.61 (1H, m, H24), 3.57 (1H, m, H30), 3.54 (1H, m, H15), 3.50 (1H, m, H37), 3.49 (1H, ddd, *J* = 9.0, 9.0, 4.0 Hz, H9), 3.44 (1H, dd, *J* = 9.0, 9.0 Hz, H12), 3.35 (1H, ddd, *J* = 12.0, 9.0, 4.5 Hz, H13), 3.34 (1H, m, H36), 3.34 (1H, m, H42), 3.32 (1H, dd, *J* = 12.0, 4.5 Hz, H34), 3.22 (1H, ddd, *J* = 10.0, 10.0, 3.0 Hz, H41), 3.21 (1H, dd, *J* = 10.0, 5.0 Hz, H45), 2.94 (1H, m, H25), 2.94 (1H, m, H28), 2.73 (1H, ddd, *J* = 16.0, 8.0, 4.0 Hz, H8), 2.60 (1H, m, H31), 2.59 (1H, m, H43), 2.59 (1H, m, H46), 2.57 (1H, m, H31), 2.56 (1H, m, H14), 2.53 (1H, m, H8), 2.40 (1H, dd, *J* = 9.0, 6.5 Hz, H53), 2.36 (1H, m, H28), 2.34 (1H, dd, *J* = 9.0, 3.5 Hz, H53), 2.26 (1H, ddd, *J* = 12.0, 4.5, 4.5 Hz, H35), 2.20 (1H, m, H25), 2.04 (1H, m, H40), 2.00 (1H, m, H50), 1.92 (1H, ddd, *J* = 12.0, 12.0, 12.0 Hz, H35), 1.90 (1H, m, H39), 1.85 (1H, ddd, *J* = 12.0, 12.0, 12.0 Hz, H14), 1.83 (1H, m, H38), 1.78 (1H, ddd, *J* = 12.0, 12.0, 12.0 Hz, H43), 1.73 (1H, m, H40), 1.67 (1H, m, H51), 1.54 (1H, m, H38), 1.38 (3H, s, Me56), 1.32 (3H, d, *J* = 7.0 Hz, Me59), 1.31 (3H, d, *J* = 6.0 Hz, Me58), 1.23 (3H, d, *J* = 6.5 Hz, Me60), 0.93 (3H, d, *J* = 7.0 Hz, Me57);

45 MALDI-TOF MS, calcd. for C₆₀H₈₆O₁₉ 1133.5661 (M+Na⁺), found for 1133.5583

[0047] Illustration of shortened marks in this application

AIBN	α, α'-azobis(isobutyronitrile)
50 Cy	cyclohexyl
DDQ	2,3-dichloro-5,6-dicyano-1,4-benzoquinone
DIBAL	diisobutylaluminumhydride
DMSO	dimethylsulfoxide
DTBMP	2,6-di-butyl-4-methylpyridine
55 Grubbs catalyst	benzylidene-bis(tricyclohexylphosphine)dichlororuthenium
HPLC	high performance liquid chromatography
Me	Methanol
NaHMDS	sodium bis(trimethylsilyl)amide


NAP	2-naphthylmethyl
Ph	phenyl
TBAF	tetrabutylammonium fluoride
Tf	trifluoromethanesulfonyl
5 THF	tetrahydrofuran
TMS	trimethylsilyl
TIPS	triisopropylsilyl

INDUSTRIAL APPLICABILITY


[0048] The present invention makes possible to provide necessary amount of said compound for progressing bio-science research or development of method for detection of ciguatera poisoned fish, and is useful for industrial use applicable as a standard sample for ciguatera food-poisoning happened in all over the world.

Claims


1. A method for preparation of CTX1B including following 10 processes,



a double bond of compound A




is oxidized by osmium tetra oxide and changed to diol derivative of compound A, transformed the diol to aldehyde by oxidation -cleavage by sodium periodate, then reduced the aldehyde to alcohol using sodium borohydride and obtain compound 1 (process 1),



alcohol of compound 1 is transformed to compound 2 using diphenyldisulfide · tributylphosphine (process 2),


5



10

said compound 2 is transformed to α chlorosulphide using N-chlorosuccinimide and synthesize compound B,


15



20

under the presence of DTBMP said compound B is joined to the ABCDE ring segments compound C as O,S-acetal using silver triflate and compound 3 is formed (process 3),

25




30

35

TIPS group of said compound 3 is removed using TBAF and form compound 4 (process 4),

40




45


50

pentafluorophenylpropiolate is joined to alcohol of said compound 4 using trimethylphosphine and compound 5 is formed (process 5),


55




15 carry out radical cyclizing reaction on said compound 5 by treating with AIBN and tintributyl hydride and form G ring part, so that compound 5 transforms to carboxylic acid compound D, then




30 transforms to methyl ester by acting trimethylsilyldiazomethane and forms compound 6 (process 6),




45 forms compound 7 (process 7) by reducing methyl ester of said compound 6 by diisobutylaluminum hydrate under lower temperature condition, then transforms to olefin by Wittig reaction,



forms compound 8 (process 8) by forming F ring part by carrying out ring closure methathesis reaction acting Grubbs catalyst to said compound 7,




synthesizes compound E, 1,2-diol of A ring side chain of which is protected by naphthylacetal, by oxidizing 6 NAP groups using DDQ and removing 5 NAP groups (process 9), then



35 carries out acid treatment on said compound E (process 10), wherein, in compounds A, B, D, E, CTX1B and compounds 1-8, NAP is 2-naphthylmethyl group, Me is methyl group, TIPS is triisopropylsilyl group, Ph is phenyl group, further, shortened mark DTBMP is 2,6-di-butyl-4-methylpyridine, TBAF is tetrabutylammonium fluoride, AIBN is α, α' -azobis(isobutyronitrile), DDQ is 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.


40 Patentansprüche

1. Verfahren zur Herstellung von CTX1B, das die folgenden 10 Arbeitsschritte einschließt



eine Doppelbindung von Verbindung A

5




10

15

wird durch Osmiumtetroxid oxidiert und in ein Diolderivat von Verbindung A umgewandelt, das Diol wird durch oxidative Spaltung mit Natriumperodat in Aldehyd umgewandelt, anschließend wird der Aldehyd unter Verwendung von Natriumborhydrid zu Alkohol reduziert, und Verbindung 1 wird erhalten (Schritt 1),

20




25

30

der Alkohol von Verbindung 1 wird unter Verwendung von Diphenyldisulfidtributylphosphin in die Verbindung 2 umgewandelt (Schritt 2),

35




40

45

die Verbindung 2 wird unter Verwendung von N-Chlorsuccinimid in α -Chlorsulfid übergeführt, und Verbindung B wird synthetisiert,

50




55

in Gegenwart von DTBMP wird die Verbindung B mit der ABCDE-Ringsegment-Verbindung C als O,S-Acetal unter Verwendung von Silbertriflat verknüpft, und Verbindung 3 wird gebildet (Schritt 3),

5

10




15

die TIPS-Gruppe der Verbindung 3 wird unter Verwendung von TBAF entfernt, und Verbindung 4 wird gebildet (Schritt 4),

20

25




30

Pentafluorphenylpropiolat wird mit dem Alkohol der Verbindung 4 unter Verwendung von Trimethylphosphin verknüpft, und Verbindung 5 wird gebildet (Schritt 5),

35

40



45


Durchführen einer radikalischen Cyclisierungsreaktion mit der Verbindung 5 durch Behandeln mit AIBN und Zinntributylhydrid und Bilden des Ring-G-Teils, so dass Verbindung 5 in die Carboxylsäureverbindung D umgewandelt wird, sodann

50

55

5

10




Umwandeln in Methylester durch Einwirken von Trimethylsilyldiazomethan und Bilden von Verbindung 6 (Schritt 6),

15

20

25




Bilden von Verbindung 7 (Schritt 7) durch Reduktion von Methylester der Verbindung 6 durch Diiodbutylaluminiumhydrid unter Niedertemperaturbedingung, dann Umwandeln in Olefin durch Wittig-Reaktion,

30

35

40




Bilden von Verbindung 8 (Schritt 8) durch Bilden des F-Ring-Teils durch Durchführen einer Ringschluss-Methathese-reaktion, wobei ein Grubbs-Katalysator auf die Verbindung 7 einwirkt,

45

50

55




Synthèse von Verbindung E, 1,2-Diol der A-Ring-Seitenkette, das durch Naphthylacetal geschützt ist, durch Oxidation von 6 NAP-Gruppen unter Verwendung von DDQ und Entfernen von 5 NAP-Gruppen (Schritt 9), dann

5

10

15



20

Durchführen von Säurebehandlung mit Verbindung E (Schritt 10), wobei in den Verbindungen A, B, D, E, CTX1B und den Verbindungen 1-8, NAP 2-Naphthylmethylgruppe bedeutet, Me Methylgruppe bedeutet, TIPS Triisopropylsilylgruppe bedeutet, Ph Phenylgruppe bedeutet, weiterhin die Abkürzung DTBMP 2,6-Dibutyl-4-methylpyridin bedeutet, TBAF Tetrabutylammoniumfluorid bedeutet, AIBN α, α' -Azobis(isobutyronitril) bedeutet, DDQ 2,3-Dichlor-5,6-dicyano-1,4-benzoquinon bedeutet.


25

Revendications

30

1. Procédé pour la préparation de CTX1B comprenant les 10 procédés suivants,

35




40

une double liaison du composé A

45

50




55

est oxydée par du tétraoxyde d'osmium et transformée en dérivé diol de composé A, le diol est transformé en aldéhyde par clivage par oxydation par du periodate de sodium, puis l'aldéhyde est réduit en alcool en utilisant du


EP 1 982 988 B1

borohydrure de sodium pour obtenir le composé 1 (procédé 1),




Composé 1

l'alcool du composé 1 est transformé en composé 2 en utilisant de la tributylphosphine de diphenylsulfure (procédé 2)



Composé 2


ledit composé 2 est transformé en α -chlorosulfure en utilisant de la N-chlorosuccinimide pour synthétiser le composé B,



Composé B


Composé C

en présence de DTBMP ledit composé B est assemblé aux segments cycliques ABCDE du composé C, sous forme de O,S-acétal en utilisant du triflate d'argent et le composé 3 est formé (procédé 3),




Composé 3

le groupe TIPS dudit composé 3 est éliminé en utilisant du TBAF pour former le composé 4 (procédé 4)




15 du pentafluorophénylpropiolate est assemblé à l'alcool dudit composé 4 en utilisant de la triméthylphosphine et le composé 5 est formé (procédé 5),



composé 5


30 conduire une réaction de cyclisation radicalaire sur ledit composé 5 par traitement avec de l'AIBN et de l'hydrure de tributyl-étain pour former la partie cyclique G, de sorte que le composé 5 se transforme en acide carboxylique du composé D, puis



se transforme en ester méthylique par l'action de triméthylsilyldiazométhane et forme le composé 6 (procédé 6),

5

10



Composé 6


15

forme le composé 7 (procédé 7) par réduction de l'ester méthylique dudit composé 6 par du diisobutylaluminium hydraté sous des conditions de basse température, puis se transforme en oléfine par réaction de Wittig,

20

25

30




Composé 7

35

forme le composé 8 (procédé 8) par formation de la partie cyclique F par conduite d'une réaction de métathèse par fermeture de cycle par action d'un catalyseur de Grubbs sur ledit composé 7,

40

45



Composé 8

50


synthétise le composé E, le 1,2-diol de la chaîne latérale du cycle A qui est protégée par du naphtylacétal, par oxydation des groupes 6 NAP en utilisant du DDQ et en éliminant les groupes 5-NAP (procédé 9), puis

55

5

10

15



Composé E

20

effectuer un traitement acide sur ledit composé E (procédé 10),
dans lequel, dans les composés A, B, D, E, CTX1B et les composés 1 à 8, NAP est le groupe 2-naphtylméthyle,
Me est le groupe méthyle, TIPS est un groupe triisopropylsilyle, Ph est le groupe phényle, de plus, l'abréviation
DTBMP est la 2,6-di-butyl-4-méthylpyridine, TBAF est le fluorure de tétrabutylammonium,
AIBN est α,α' -azobis(isobutyronitrile), DDQ est 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- *Proc. Natl. Acad. Sci. U.S.A.*, 2004, vol. 101, 12013-12018 **[0004]**
- *J. Am. Chem. Soc.*, 2003, vol. 125, 7608-7612 **[0004]**
- *Science*, 2001, vol. 294, 1904-1907 **[0005]**
- *J. Org. Chem.*, 2004, vol. 69, 2797-2804 **[0008]**
[0012]
- *J. Org. Lett.*, 2004, vol. 6, 751-754 **[0008]** **[0010]**
[0014]